In line with the path of progress in clinical trials on AZD5363-treated breast cancer cells to FDA approval [18], Choi et al. assessed the effect of the drug on the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway. This evidence concerns the gene AKT1 and breast cancer.